English Name | Dosage Form & Strength | Regulatory Status | Developable Market | Project Type |
Mirabegron | Sustained release tablet:25mg、50mg | Approved by EU | All markets | License-in |
Abacavir Sulfate | Injection:20mg/ml, Tablet:300mg | Approved by US-FDA | All markets | License-in |
Ritonavir | Tablet:100mg | Approved by US-FDA | All markets | License-in |
Roflumilast | Tablet:500mg | Approved by US-FDA | All markets | License-in |
Etomidate Injectable Emulsion | Injection:2mg/ml | Approved by EU Approved by US-FDA | All markets | License-in |
Atazanavir Sulfate | Capsule:150mg | Approved by US-FDA | All markets | License-in |
Colesevelam Hydrochloride Tablets | Tablet:625mg | Approved by US-FDA | All markets | License-in |
Lurasidone Hydrochloride Tablets | Tablet:20mg、40mg、60mg、80mg | Approved by US-FDA | All markets | License-in |
Teriflunomide Tablets | Tablet:7 mg 、14 mg | Approved by US-FDA | All markets | License-in |
Pramipexole | Tablet:0.125mg、0.25mg、0.5mg、0.75mg、1mg、1.5mg | Approved by US-FDA | All markets | License-in |
Efavirenz | Tablet:600mg | Approved by EU Approved by US-FDA | All markets | License-in |
Fosaprepitant | Injection:115mg/10ml | Easy to register in China; Approved by US-FDA | All markets | License-in |
Dofetilide | Tablet/Capsule:125mcg,250mcg,500mcg | Approved by US-FDA | All markets | License-in |
Brivaracetam | Tablet:10 mg,25 mg,50 mg,75 mg,100 mg | Easy to register in China; Approved by US-FDA | All markets | License-in |
Thiotepa | Injection:10mg/ml | Clinical research have done on the basis of original drugs; Approved by US-FDA | All markets | License-in |
Bosutinib | Tablet:100 mg、400 mg、500 mg | Clinical research have done on the basis of original drugs; Approved by US-FDA | All markets | License-in |
Linagliptin | Tablet,Sustained release tablet:5mg | Approved by US-FDA | All markets | License-in |
metformin+linagliptin | Tablet,Sustained release tablet:2.5mg: 850mg | Approved by US-FDA | All markets | License-in |
empagliflozin | Tablet:1g,10g,100g,1kg,10kg,100kg | Approved by US-FDA | All markets | License-in |
Levosimendan Injection | Injection:5ml,12.5mg | Approved by EU | All markets | License-in |
OSELTAMIVIR PHOSPHATE | Dry Suspension:6mg/ml | Approved by US-FDA | All markets | License-in |
Iron sucrose injection | Injection:100mg/5ml | Approved by US-FDA | All markets | License-in |
ESCITALOPRAM OXALATE | Oral Solution:5mg/5ml | Approved by EU Approved by US-FDA | All markets | License-in |
Posaconazole | Injection:200 mg/5 ml | Approved by Eastern Europe | All markets | License-in |
sugammadex sodium | Injection: 500mg/5ml;200mg/2ml | Filing in US-FDA | All markets | License-in |
BILASTINE | Film coated tablet: 20mg | Filing completed in EU and US-FDA in the fourth quarter of 2020 | All markets | License-in |
RASAGILINE MESYLATE | Tablet:0.5mg,1mg | Approved by EU | All markets | License-in |
Chloroquine Diphosphate | Tablet:250mg,500mg | Ready to list on US-FDA | All markets | License-in |
Doxylamine succinate+Pyridoxine HCl | Sustained release tablet:10 mg | Filing in US-FDA | All markets | License-in |
Tenofovir Alafenamide Fumarate | Tablet:25 mg | Filing in US-FDA | All markets | License-in |
Tolvaptan | Tablet:15 and 30 mg | Filing in US-FDA | All markets | License-in |
Dolutegravir;Lamivudine;Tenofovir Disoproxil Fumarate | Tablet:50 and 300 mg | Filing in US-FDA | All markets | License-in |
Pentoxifylline | Sustained release tablet:400mg Injection:100mg/5ml;100mg/2ml | Approved by EU Approved by US-FDA | All markets | License-in |
Azelaic Acid | GEL:15% | Approved by US-FDA | All markets | License-in |
Calcipotriene | Cream;0.005% Ointment:0.005% | Approved by US-FDA | All markets | License-in |
Clotrimazole and Betamethasone Dipropionate | Cream:1% | Approved by US-FDA | All markets | License-in |
Lidocaine | Ointment:5% | Approved by US-FDA | All markets | License-in |
Dabigatran Etexilate Capsules | Capsule:75mg,110mg,150mg | Approved by US-FDA | All markets | License-in |
Ezetimibe simvastatin | Tablet:10mg,20mg,40mg,80mg | Approved by EU Approving in US-FDA | All markets | License-in |
Cabazitaxel | Injection:60mg/1.5ml (40mg/ml) | Approving in US-FDA | All markets | License-in |
Etonogestrel | Implant: 68mg Vaginal ring:0.12mg/24 Hours | Approved by EU | All markets | License-in |
Deferasirox | Dispersible tablet: 90 mg, 180 mg, 360 mg | Approving in US-FDA | All markets | License-in |
Ivabradine | Tablet:2.5mg、5mg、7.5 mg | Approved by EU | All markets | License-in |
Ibandronate | Tablet:150 mg | Approved by EU | All markets | License-in |
Dasatinib | Tablet: 20mg、 50mg、 70mg、80mg、100mg、140mg | Approved by EU | All markets | License-in |
Chloroquine Diphosphate | Tablet:250mg | Approved by EU | All markets | License-in |
Eplerenone | Tablet:25mg,50 mg | Approved by EU | All markets | License-in |
Rasagiline | Tablet:1 mg | Approved by EU | All markets | License-in |
Anagrelide | Capsule:0.5mg, 1 mg | Approved by EU | All markets | License-in |
Bendamustine | Injection:25mg/vial, 100 mg/vial | Approved by EU | All markets | License-in |
Erlotinib | Tablet:25mg,100 mg,150mg | Approved by EU | All markets | License-in |
Sevelamer | Tablet:800mg Suspending Agent:2.4mg/packet、800mg/packet | Available for European and American markets | All markets | License-in |